Serving the Underserved: Are We Overlooking HoFH Patients?
Dean G. Karalis, MD, FNLA, Linda C. Hemphill, MD, FNLA, G. Kees Hovingh, MD, PhD, MBA, Anne C. Goldberg, MD, FNLA, Jerome D. Cohen, MD, FNLA
The National Lipid Association has conducted a survey to better understand the diagnosis and treatment of patients with homozygous familial hypercholesterolemia (HoFH) among primary care professionals. The survey was completed by primary care providers across the United States and included questions to identify gaps in knowledge and practice within the health care community and rare disease space.
It is now recognized that HoFH is more common than early estimates predicted with up to 1 in 300,000 Americans having HoFH. HoFH patients are usually seen first by primary care providers. These patients develop atherosclerotic vascular disease at an early age and most remain undiagnosed and undertreated.
View the resources below to learn of common trends found in our survey regarding the diagnosis and treatment of HoFH patients among primary care providers, and to understand what is needed to ensure appropriate treatment of this high-risk population.
This survey was supported in part by Aegerion, Inc. and REGENXBIO Inc.
This page was last updated: Jan 18, 2021